Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018

  • ID: 4576117
  • Report
  • 37 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Destiny Pharma Ltd
  • MGB Biopharma Ltd
  • Syntiron LLC
  • Techulon Inc
  • Valevia UK Ltd
  • MORE
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline landscape.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warm to the touch, fever and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures.

Report Highlights:

This latest pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Destiny Pharma Ltd
  • MGB Biopharma Ltd
  • Syntiron LLC
  • Techulon Inc
  • Valevia UK Ltd
  • MORE
Introduction

Report Coverage

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development

Destiny Pharma Ltd

MGB Biopharma Ltd

Syntiron LLC

Techulon Inc

Valevia UK Ltd

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Drug Profiles

Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGBBP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Staphylococcus aureus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones

Featured News & Press Releases

Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Ltd, H1 2018

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Ltd, H1 2018

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Syntiron LLC, H1 2018

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon Inc, H1 2018

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Valevia UK Ltd, H1 2018

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, H1 2018

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Destiny Pharma Ltd
  • MGB Biopharma Ltd
  • Syntiron LLC
  • Techulon Inc
  • Valevia UK Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll